Study guide

33.4 Analgesics for Acute Dental Pain

Overseas Registration Examination ORE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: ORE Part 1 — Exam Blueprint, Logistics and Strategy

1.1 Structure and Format of ORE Part 1 1.2 The Official Blueprint and Preparing for Practice 1.3 Eligibility, Fees, Attempts and Time Limits

2 Chapter 2: Anatomy of the Head and Neck

2.1 The Trigeminal Nerve and Dental Innervation 2.2 The Facial Nerve and Parotid Region 2.3 The Temporomandibular Joint and Muscles of Mastication 2.4 The Infratemporal Fossa and Spread of Odontogenic Infection

3 Chapter 3: Dental Anatomy, Morphology and Occlusion

3.1 Permanent and Primary Tooth Morphology 3.2 Functional Occlusion: Centric Relation, Guidance and Interferences 3.3 Classifying Occlusion: Angle and BSI Incisor Relationships

4 Chapter 4: Genetics, Embryology and Odontogenesis

4.1 Stages of Odontogenesis and Molecular Signalling 4.2 Amelogenesis and Enamel Microstructure 4.3 Dentinogenesis and the Pulp-Dentine Complex 4.4 Cementum, the Periodontal Ligament and Oral Mucosa 4.5 Genetic and Developmental Dental Anomalies

5 Chapter 5: Oral Biology and Salivary Physiology

5.1 Salivary Gland Anatomy, Microarchitecture and Innervation 5.2 Salivary Secretion, Flow Rates and Autonomic Control 5.3 Salivary Buffering Systems and Protective Macromolecules 5.4 Physiology of Mastication and Deglutition 5.5 Taste, Lingual Papillae and Gustatory Pathways 5.6 Xerostomia, Sjogren's Syndrome and Salivary Diagnostics

6 Chapter 6: Physiology of the Major Body Systems

6.1 Cardiovascular and Respiratory Physiology 6.2 Renal, Endocrine and Gastrointestinal Physiology 6.3 Haematology and Haemostasis 6.4 Neurophysiology, Pain and the Autonomic Nervous System

7 Chapter 7: Bone Biology, Calcium Homeostasis and Healing

7.1 Microstructure and Architecture of Alveolar Bone 7.2 Bone Remodelling and the RANK/RANKL/OPG Axis 7.3 Endocrine Control of Calcium and Phosphate 7.4 Extraction Socket Healing and Ridge Resorption 7.5 Impaired Healing: MRONJ, Osteoradionecrosis and Systemic Risk

8 Chapter 8: Oral Microbiology and Biofilm Ecology

8.1 The Oral Microbiome and Biofilm Development 8.2 Cariogenic Microbiology: Mutans Streptococci and Lactobacilli 8.3 Ecological Hypotheses of Dental Caries 8.4 Biofilm Tolerance and the Case for Mechanical Plaque Control

9 Chapter 9: Immunology Relevant to Oral Disease

9.1 Innate Mucosal Immunity and Gingival Crevicular Fluid 9.2 Cellular Immunity in the Periodontium 9.3 Microbial Pathogenesis: Complexes and Keystone Pathogens 9.4 Host-Mediated Tissue Destruction 9.5 Hypersensitivity Reactions in Dental Practice 9.6 Autoimmune Mucocutaneous Bullous Disease 9.7 Immunodeficiency and Oral HIV Manifestations

10 Chapter 10: General Pathology and Neoplasia

10.1 Cellular Adaptation and Mechanisms of Cell Death 10.2 Inflammation, Wound Healing and Repair 10.3 Principles of Neoplasia and Carcinogenesis 10.4 TNM Staging of Oral Cavity Carcinoma

11 Chapter 11: Statistics and Research Methods

11.1 Study Designs and the Hierarchy of Evidence 11.2 Descriptive and Inferential Statistics 11.3 Diagnostic Test Performance 11.4 Critical Appraisal, Bias and Research Governance

12 Chapter 12: Human Disease: Cardiovascular and Respiratory

12.1 Infective Endocarditis and NICE CG64 12.2 Hypertension and Blood Pressure Thresholds for Dental Care 12.3 Angina, Myocardial Infarction and Antiplatelet Therapy 12.4 Asthma, COPD and Respiratory Emergencies

13 Chapter 13: Human Disease: Endocrine, Haematological and Renal

13.1 Diabetes Mellitus and the Periodontal Axis 13.2 Congenital Bleeding and Clotting Disorders 13.3 Anticoagulants and Antiplatelets: The SDCEP Protocol 13.4 Chronic Kidney Disease and Haemodialysis

14 Chapter 14: Human Disease: Gastrointestinal, Hepatic and Neurological

14.1 Gastrointestinal Disease and Intrinsic Dental Erosion 14.2 Liver Disease, Coagulopathy and Viral Hepatitis 14.3 Epilepsy, Stroke and Transient Ischaemic Attack 14.4 Trigeminal Neuralgia, Bell's Palsy and Giant Cell Arteritis

15 Chapter 15: Oral Aspects of Human Disease

15.1 Oral Manifestations of Systemic Disease 15.2 Orofacial Pain and Temporomandibular Disorders 15.3 Dry Mouth, Altered Taste and Halitosis

16 Chapter 16: Infection Prevention and Control

16.1 The Decontamination Cycle, Sterilization and Waterlines 16.2 Routes of Transmission and Blood-Borne Viruses

17 Chapter 17: Dental Materials

17.1 Dental Amalgam: Metallurgy and UK Regulation 17.2 Resin Composites: Chemistry and Placement 17.3 Dental Adhesive Systems 17.4 Acid Etching, the Hybrid Layer and MMP Degradation 17.5 Glass Ionomer Cements, RMGICs and Compomers 17.6 Impression Materials and Digital Scanning 17.7 Luting Cements and Adhesive Conditioning Protocols 17.8 Dental Ceramics and Cast Alloys 17.9 Gypsum Products, Waxes and Denture Base Polymers

18 Chapter 18: Behavioural Sciences Relevant to Oral Health Care

18.1 Health Behaviour Models and Behaviour Change 18.2 Dental Anxiety and Phobia 18.3 Psychosocial and Sociological Determinants of Oral Health

19 Chapter 19: Patient Assessment and Diagnosis

19.1 History Taking and Clinical Examination 19.2 Special Investigations and Reaching a Diagnosis

20 Chapter 20: Treatment Planning and Risk-Based Care

20.1 Treatment Planning and Sequencing 20.2 Risk Assessment, Recall Intervals and Preventive Planning

21 Chapter 21: Cariology and Caries Risk Assessment

21.1 Caries Pathogenesis and the Stephan Curve 21.2 Histopathology of Enamel and Dentinal Caries 21.3 Caries Diagnosis, ICDAS and Risk Assessment

22 Chapter 22: Operative Dentistry and Minimal Intervention

22.1 Minimal Intervention and Selective Caries Removal 22.2 Pulp Vitality Assessment and Biological Pulp Capping 22.3 Cavity Design, the C-Factor and Margin Geometry

23 Chapter 23: Endodontics

23.1 Pulp Histology and the Low-Compliance Environment 23.2 Pulpal Neurophysiology and Dentine Hypersensitivity 23.3 Pulpal and Periapical Diagnostic Terminology 23.4 Endodontic Diagnostic Testing 23.5 Access Cavity Design and Canal Configurations 23.6 Working Length Determination and Canal Preparation 23.7 Chemical Disinfection and Irrigant Activation 23.8 Medicaments, Obturation Materials and Techniques 23.9 Restoring Endodontically Treated Teeth 23.10 Endodontic Emergencies, Cracked Teeth and Root Fracture

24 Chapter 24: Periodontology

24.1 The 2018 Classification and Periodontal Health 24.2 Plaque-Induced and Non-Plaque-Induced Gingival Disease 24.3 Staging and Grading Periodontitis 24.4 Peri-Implant Disease and Systemic Risk Factors 24.5 The Basic Periodontal Examination 24.6 Simplified BPE in Children and Full Periodontal Charting 24.7 Furcation Involvement, Mobility and Occlusal Trauma 24.8 The BSP Stepwise Treatment Framework 24.9 Periodontal Instrumentation and Healing 24.10 Re-Evaluation, Endpoints and Periodontal Surgery 24.11 Crown Lengthening, Supracrestal Attachment and Supportive Care

25 Chapter 25: Fixed Prosthodontics

25.1 Biomechanical Principles of Tooth Preparation 25.2 Margin Design and the Supracrestal Attachment 25.3 Bridge Design and Resin-Bonded Bridges 25.4 Gingival Retraction, Provisionals and Temporary Cements

26 Chapter 26: Removable Prosthodontics

26.1 Removable Partial Dentures: Classification, Design and Surveying 26.2 Complete Dentures: Principles, Impressions and Jaw Registration

27 Chapter 27: Paediatric Dentistry

27.1 Primary Tooth Anatomy and Caries Management Strategies 27.2 Preformed Metal Crowns and the Hall Technique 27.3 Pulp Therapy in Primary Teeth 27.4 Extractions in the Primary Dentition 27.5 Non-Pharmacological Behaviour Management 27.6 Inhalation Sedation in Paediatric Dentistry 27.7 The Developing Dentition and Space Management 27.8 Serial Extraction and Non-Nutritive Sucking Habits

28 Chapter 28: Dental Traumatology

28.1 Trauma Assessment and Fractures of Permanent Teeth 28.2 Luxation Injuries, Avulsion and Replantation 28.3 Primary Tooth Trauma and Splinting Specifications

29 Chapter 29: Orthodontics

29.1 Extraoral Orthodontic Assessment 29.2 Intraoral Occlusal Assessment 29.3 Skeletal Pattern and Cephalometric Analysis 29.4 IOTN and NHS Treatment Eligibility 29.5 Upper Removable Appliances 29.6 Functional and Fixed Appliances 29.7 Biology of Orthodontic Tooth Movement 29.8 Orthodontic Risks and Retention

30 Chapter 30: Oral Surgery

30.1 Exodontia Biomechanics and Instrument Selection 30.2 Surgical Flap Design, Bone Removal and Suturing 30.3 Third Molar Surgery and NICE Guidance 30.4 Dry Socket and Oroantral Communication 30.5 Odontogenic Infection and Fascial Space Spread

31 Chapter 31: Oral Medicine

31.1 Recurrent Aphthous Stomatitis 31.2 Oral Candidiasis 31.3 Viral Oral Infections 31.4 Reactive Soft Tissue Lesions and the Epulides 31.5 Oral Potentially Malignant Disorders 31.6 Oral Squamous Cell Carcinoma, Urgent Referral and Biopsy

32 Chapter 32: Oral Pathology

32.1 Odontogenic and Non-Odontogenic Cysts 32.2 Odontogenic Tumours 32.3 Obstructive and Reactive Salivary Gland Disease 32.4 Salivary Gland Neoplasms

33 Chapter 33: Therapeutics and Prescribing

33.1 Local Anaesthetic Chemistry and Mechanism of Action 33.2 UK Local Anaesthetic Formulations 33.3 Vasoconstrictors, Maximum Doses and Systemic Toxicity 33.4 Analgesics for Acute Dental Pain 33.5 Antimicrobial Stewardship and First-Line Regimens 33.6 Antifungal and Antiviral Therapeutics

34 Chapter 34: Medical Emergencies in Dental Practice

34.1 The ABCDE Approach and the Emergency Drug Kit 34.2 Anaphylaxis and Acute Coronary Syndrome 34.3 Hypoglycaemia, Acute Asthma and Seizures 34.4 Syncope, Adrenal Crisis, Choking and Resuscitation

35 Chapter 35: Dental Radiology and Radiation Protection

35.1 Radiation Physics, Filtration and Collimation 35.2 Intraoral, Bitewing and Occlusal Projections 35.3 Dental Panoramic Tomography: Principles, Positioning and Errors 35.4 Lateral Cephalometry and Cone Beam CT 35.5 Systematic Reporting and Radiographic Caries Diagnosis 35.6 Radiology of Periodontal Bone Loss and Jaw Lesions 35.7 Radiographic Quality Assurance 35.8 IRR17 and IR(ME)R 2017

36 Chapter 36: Special Care Dentistry and Conscious Sedation

36.1 Special Care Dentistry, Risk Stratification and Sedation Principles 36.2 Inhalation Sedation with Nitrous Oxide 36.3 Intravenous Sedation with Midazolam 36.4 Oral Sedation and General Anaesthesia Referral

37 Chapter 37: Dental Public Health

37.1 Delivering Better Oral Health and the Fluoride Toolkit 37.2 Oral Health Epidemiology and Indices 37.3 Inequalities, Water Fluoridation and Population Prevention 37.4 NHS Dental Services, Access and Commissioning

38 Chapter 38: Communication and Interpersonal Skills

38.1 Patient Communication and Shared Decision-Making 38.2 Breaking Bad News, Complaints and the Duty of Candour 38.3 Referrals, Records and Communication with the Team

39 Chapter 39: Consent and Capacity

39.1 Valid Consent and the Montgomery Standard 39.2 The Mental Capacity Act 2005 39.3 Best Interests Decisions and Lasting Power of Attorney 39.4 Consent in Children and Young People 39.5 Safeguarding Children and Vulnerable Adults 39.6 Confidentiality, Data Protection and Lawful Disclosure

40 Chapter 40: Clinical Professionalism and the GDC

40.1 The General Dental Council and Standards Principles 1 to 4 40.2 GDC Standards: Principles 5 to 9 40.3 The GDC Fitness to Practise Process 40.4 Clinical Governance and the Audit Cycle

41 Chapter 41: Health and Safety Law in Dental Practice

41.1 Health and Safety Legislation, COSHH, RIDDOR and Sharps

42 Chapter 42: Self-Management and Professional Development

42.1 Enhanced CPD, Lifelong Learning and Reflective Practice 42.2 Managing Time, Stress and Clinical Wellbeing 42.3 Leadership, Delegation and Practice Management

33.4 Analgesics for Acute Dental Pain

Key Takeaways Explain This Topic AI

Paracetamol is dosed at 500 mg to 1 g every four to six hours to a strict maximum of 4 g in 24 hours.

Paracetamol overdose saturates conjugation pathways so that CYP2E1 generates NAPQI, which depletes glutathione and causes centrilobular hepatic necrosis.

N-acetylcysteine replenishes glutathione and is most effective within 8 to 12 hours of ingestion.

Ibuprofen is dosed at 400 to 600 mg three to four times daily with food, to a maximum of 2.4 g in 24 hours.

Ibuprofen 400 mg combined with paracetamol 1 g gives better analgesia for acute dental pain than either drug alone or than codeine combinations.

Last updated: September 2026

Analgesic Ladder for Acute Dental Pain

Dental pain is predominantly inflammatory , triggered by cellular membrane disruption, phospholipase A 2 A_2 A 2 ​ activation, and the arachidonic acid cascade. The resulting generation of prostaglandins ( P G E 2 , P G I 2 PGE_2, PGI_2 PG E 2 ​ , PG I 2 ​ ) sensitizes peripheral nociceptive A-delta and C fibres to inflammatory mediators such as bradykinin and histamine. Arachidonic Acid Cascade

  • │
  • ┌────────────────────┴────────────────────┐
  • ▼ ▼
  • Cyclooxygenase-1 (COX-1) Cyclooxygenase-2 (COX-2)
  • Constitutive / Physiological - Inducible / Inflammatory
  • Gastric mucosal protection (PGE2) - Pain, fever, hyperalgesia
  • Renal blood flow autoregulation - Endothelial prostacyclin (PGI2)
  • Platelet Thromboxane A2 (haemostasis)
  • │ │
  • └────────────────────┬────────────────────┘
  • │
  • Inhibited by Non-Selective NSAIDs
  • (e.g., Ibuprofen, Naproxen)
  • 1. Paracetamol (Acetaminophen)

Mechanism of Action: Primarily acts as a central analgesic and antipyretic. It inhibits central nervous system prostaglandin synthesis (putative COX-3 or peroxidase catalytic site inhibition within neural environments where peroxide concentrations are low). It possesses negligible peripheral anti-inflammatory activity. Recent evidence also identifies active metabolite AM404 , which acts on cannabinoid C B 1 CB_1 C B 1 ​ receptors and stimulates descending serotonergic inhibitory pain pathways.

Adult Dosing: 500 mg to 1000 mg every 4–6 hours as required, up to a strict maximum of 4000 mg (4 g) in 24 hours .

Hepatotoxicity & Toxicological Mechanism:

In therapeutic doses, 85–90% of paracetamol is cleared via hepatic phase II glucuronidation and sulfation into benign metabolites. Only 5–10% is metabolized by cytochrome P450 (predominantly CYP2E1 ) into the highly reactive, electrophilic, hepatotoxic intermediate N-acetyl-p-benzoquinone imine (NAPQI) .

Under normal conditions, NAPQI is instantly detoxified by conjugation with endogenous hepatic glutathione into non-toxic mercapturic acid conjugates excreted in urine.

In overdose ( > 75 − 150 mg/kg >75-150\text{ mg/kg} > 75 − 150 mg/kg or > 4 − 8 g >4-8\text{ g} > 4 − 8 g ) , the protective glucuronide and sulfate pathways become completely saturated. Excess drug is shunted to CYP2E1, generating massive amounts of NAPQI that deplete hepatic glutathione stores. Unconjugated NAPQI binds covalently to cysteinyl sulfhydryl groups on hepatocyte mitochondrial proteins, causing widespread acute centrilobular hepatic necrosis and fulminant liver failure.

Antidotal Therapy: Intravenous N-acetylcysteine (NAC) acts as a glutathione precursor and synthetic sulfhydryl donor, replenishing glutathione stores and directly conjugating NAPQI if administered within 8–12 hours of acute ingestion.

2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Mechanism of Action: Competitive, reversible inhibition of both cyclooxygenase isoforms: COX-1 (constitutive) and COX-2 (inducible). By halting prostaglandin E 2 E_2 E 2 ​ synthesis at the peripheral site of tissue injury, NSAIDs directly suppress peripheral nociceptor sensitization, providing superior analgesia for inflammatory odontogenic conditions.

Adult Dosing (Ibuprofen): 400 mg to 600 mg three to four times daily (tds/qds) taken with or after food, up to a maximum of 2400 mg (2.4 g) in 24 hours .

High-Yield Clinical Contraindications & Risks:

Gastrointestinal Ulceration & Bleeding: Inhibition of COX-1 shuts down gastric mucosal prostaglandin ( P G E 2 , P G I 2 PGE_2, PGI_2 PG E 2 ​ , PG I 2 ​ ) production, which normally promotes protective bicarbonate and mucus secretion and maintains mucosal blood flow. Concomitant use with systemic corticosteroids, SSRIs, or anticoagulants dramatically amplifies haemorrhage risk.

Renal Impairment & The "Triple Whammy": Renal prostaglandins maintain vasodilation of the afferent renal arteriole , preserving glomerular filtration rate (GFR). NSAID-induced prostaglandin inhibition causes unmitigated afferent arteriolar constriction. Co-prescribing NSAIDs with an ACE inhibitor (which dilates the efferent arteriole) and a Diuretic (which reduces plasma volume) precipitates severe acute tubular necrosis and acute renal failure (the classic "Triple Whammy" ).

Aspirin-Exacerbated Respiratory Disease (AERD) / NSAID-Sensitive Asthma: Up to 10–20% of adult asthmatics possess AERD. Cyclooxygenase blockade shunts arachidonic acid metabolism down the alternative 5-lipoxygenase (5-LOX) enzymatic pathway. This causes massive overproduction of cysteinyl leukotrienes ( L T C 4 , L T D 4 , L T E 4 LTC_4, LTD_4, LTE_4 L T C 4 ​ , L T D 4 ​ , L T E 4 ​ ), triggering life-threatening bronchoconstriction, mucosal oedema, and rhinorrhoea.

Cardiovascular Thrombotic Events (MHRA Guidance): Selective COX-2 inhibitors and high-dose ibuprofen ( ≥ 2400 mg/day \ge 2400\text{ mg/day} ≥ 2400 mg/day ) suppress vascular endothelial prostacyclin ( P G I 2 PGI_2 PG I 2 ​ , an anti-thrombotic vasodilator) without inhibiting platelet thromboxane A 2 A_2 A 2 ​ ( T X A 2 TXA_2 TX A 2 ​ , a pro-thrombotic vasoconstrictor). This shifts the haemostatic balance toward thrombosis, increasing the risk of myocardial infarction and stroke. Contraindicated in established congestive heart failure (NYHA II–IV), ischaemic heart disease, and peripheral arterial disease.

  • 3. Synergistic Multimodal Regimens vs. Opioids Pain Relief Comparison
  • Regimen Number Needed to Treat (NNT)*
  • ────────────────────────────────────────────────────────────────────────────────────────
  • Ibuprofen 400 mg + Paracetamol 1000 mg (Combined) ███ 1.5 (Exceptional)
  • Ibuprofen 400 mg alone ████ 2.4 (Good)
  • Paracetamol 1000 mg alone ██████ 3.6 (Moderate)
  • Codeine 60 mg alone █████████████ 16.7 (Poor)
  • ────────────────────────────────────────────────────────────────────────────────────────

*NNT: Lower values denote superior clinical efficacy (proportion of patients achieving >=50% pain relief).

The Evidence-Based Dual Regimen: High-quality Cochrane systematic reviews establish that co-administering Paracetamol 1000 mg plus Ibuprofen 400 mg provides far greater pain relief (NNT ~1.5) than either drug alone, with longer duration and fewer adverse events. The mechanisms are complementary: peripheral prostaglandin suppression (ibuprofen) combined with central nociceptive attenuation (paracetamol).

Opioids in Dentistry (Codeine, Dihydrocodeine, Tramadol):

Opioids act centrally on μ \mu μ -opioid receptors to alter pain perception, but have no peripheral anti-inflammatory action . They are ineffective against inflammatory dental pain when compared to NSAIDs.

Pharmacogenetic Trap: Codeine is an inactive prodrug that requires metabolic bioactivation to morphine via hepatic CYP2D6 . In the UK population, approximately 7–10% of individuals are poor metabolisers who obtain zero analgesic relief from codeine, while 1–2% are ultra-rapid metabolisers who generate rapid, toxic concentrations of morphine, risking fatal respiratory depression.

Adverse effects include severe nausea, vomiting, dizziness, constipation, sedation, cognitive impairment, and rapid physiological dependence. Codeine and other opioids have no place as routine dental analgesics.

Sections you finish are checked off in the contents.

  • Up Next
  • 33.5 Antimicrobial Stewardship and First-Line Regimens
  • Continue learning